Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo shows promise against aggressive head and neck cancer

NCT ID NCT07465276

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Mar 24, 2026 · Last updated Apr 29, 2026 · Updated 9 times

Summary

This study tests whether giving two drugs—ficerafusp alfa and pembrolizumab—before surgery can shrink tumors in people with advanced head and neck cancer. About 32 participants with resectable, PD-L1-positive tumors will receive the combination, then have surgery. The main goal is to see if at least half the tumor disappears after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK